Regenxbio, a Rockville, Maryland-based gene therapy-focused biotech company, closed $70.5m in Series D funding.
The round, which brought total funding to more than $110m, was led by Vivo Capital, Venrock and Brookside Capital with participation from a fund managed by Janus Capital Management, Jennison Associates, Perceptive Advisors, QVT Financial, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management, Foresite Capital Management, RTW Investments, two undisclosed blue-chip investment funds, and existing investors Deerfield Management and Fidelity Biosciences. In conjunction with the financing, Dr. Edgar Engleman, Managing Partner of Vivo Capital, joined Regenxbio’s board of directors.
The company intends to use the funds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, expand its team and add to its current pipeline of innovative AAV gene therapies.
Led by Ken Mills, President and CEO, Regenxbio is currently leveraging its proprietary NAV® Technology to develop treatments for central nervous system (CNS) and retinal diseases – such as Hurler Syndrome (MPS I), Hunter Syndrome (MPS II) and wet age-related macular degeneration – as well as other diseases in which gene therapy can make a meaningful difference in patients’ lives. In addition to its own programs, the company has granted 16 commercial licenses for the development of NAV Technology-based treatments.